廣告
香港股市 已收市

  • 恒指

    18,079.61
    -150.58 (-0.83%)
     

  • 國指

    6,392.58
    -70.37 (-1.09%)
     

  • 上證綜指

    3,086.81
    -4.86 (-0.16%)
     

  • 滬深300

    3,579.92
    -14.39 (-0.40%)
     

  • 美元

    7.8187
    +0.0020 (+0.03%)
     

  • 人民幣

    0.9256
    +0.0010 (+0.11%)
     

  • 道指

    38,686.32
    +574.84 (+1.51%)
     

  • 標普 500

    5,277.51
    +42.03 (+0.80%)
     

  • 納指

    16,735.02
    -2.06 (-0.01%)
     

  • 日圓

    0.0494
    -0.0002 (-0.32%)
     

  • 歐元

    8.4783
    +0.0106 (+0.13%)
     

  • 英鎊

    9.9610
    +0.0110 (+0.11%)
     

  • 紐約期油

    77.18
    -0.73 (-0.94%)
     

  • 金價

    2,347.70
    -18.80 (-0.79%)
     

  • Bitcoin

    67,737.63
    +506.74 (+0.75%)
     

  • CMC Crypto 200

    1,427.56
    -1.01 (-0.07%)
     

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks Equity Research
·2 分鐘文章

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why This 1 Growth Stock Should Be On Your Watchlist

For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.

廣告

Penumbra (PEN)

Headquartered in Alameda, CA, Penumbra, as a global healthcare company, designs, develops, manufactures and markets innovative products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It has a broad portfolio that addresses challenging medical conditions in markets with significant unmet needs.

PEN boasts a Growth Style Score of B and VGM Score of B, and holds a Zacks Rank #2 (Buy) rating. Its bottom-line is projected to rise 36.8% year-over-year for 2024, while Wall Street anticipates its top line to improve by 17.5%.

One analyst revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.01 to $2.86 per share. PEN also boasts an average earnings surprise of 26%.

Looking at cash flow, Penumbra is expected to report cash flow growth of 255.5% this year; PEN has generated cash flow growth of 34.7% over the past three to five years.

PEN should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Penumbra, Inc. (PEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research